Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis

Yamasaki, Yoshioki; Yamada, Hisakata; Yamasaki, Masaomi; Ohkubo, Michiko; Azuma, Kohei; Matsuoka, Shin; Kurihara, Yasuyuki; Osada, Hiroaki; Satoh, Makoto; Ozaki, Shoichi

doi:10.1093/rheumatology/kel112

Cited by 191 publications

(94 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Takada et al reported that when comparing the results from 20 active cases of DM/PM-complicated IP, in which only additional immunosuppressive agents were added if corticosteroid alone did not result in a favorable response, with 14 additional cases in which immunosuppressive agents were combined with corticosteroids, the combination therapy led to a higher survival rate . Other clinical trials reported similar results (Yamasaki, 2007, Kotani, 2008. These reports indicate that early combined therapy is more effective than combining additional agents at a later time; as a result, this maximizes the effectiveness of the immunosuppressant.…”

Section: Treatment Of Ipsupporting

confidence: 52%

“…In the initial case reports, the effects of IV-CY were variable. Yamasaki et al administered IV-CY at doses of 300 to 800 mg/m 2 6 times every 4 weeks in addition to steroids to 17 patients with DM/PMcomplicated IP (Yamasaki, 2007). Dyspnea improved in 11 patients, %VC improved by 10% or more in 8 patients, and the chest CT score improved in 9 patients.…”

Section: Cyclophosphamidementioning

confidence: 99%

See 1 more Smart Citation

Interstitial Pneumonia in Dermatomyositis

Takeuchi¹,

Kotani²,

Makino³

2012

Neuromuscular Disorders

View full text Add to dashboard Cite

Section: Treatment Of Ipsupporting

confidence: 52%

Section: Cyclophosphamidementioning

confidence: 99%

Interstitial Pneumonia in Dermatomyositis

Takeuchi¹,

Kotani²,

Makino³

2012

Neuromuscular Disorders

View full text Add to dashboard Cite

“…Several retrospective studies suggest its utility as second- [94] or third-line of treatment in chronic ILD (table 5) [93,95]. Its use as a first-line treatment or in refractory cases of rapidly progressing ILD needs to be further explored, with anecdotal responses reported in four patients in three studies [62,93,94].…”

Section: Tacrolimusmentioning

confidence: 99%

Idiopathic inflammatory myopathies and the lung

et al. 2015

View full text Add to dashboard Cite

Idiopathic inflammatory myositis (IIM) is a group of rare connective tissue diseases (CTDs) characterised by muscular and extramuscular signs, in which lung involvement is a challenging issue. Interstitial lung disease (ILD) is the hallmark of pulmonary involvement in IIM, and causes morbidity and mortality, resulting in an estimated excess mortality of 50% in some series. Except for inclusion body myositis, these extrapulmonary disorders are associated with the general and visceral involvement frequently found in other CTDs including fever, Raynaud's phenomenon, arthralgia, nonspecific cutaneous modifications and ILD, for which the prevalence is estimated to be up to 65%. Substantial heterogeneity exists within the spectrum of IIMs, and each condition is associated with various frequencies and subtypes of pulmonary involvement. This heterogeneity is partly related to the presence of various autoantibodies encompassing anti-synthetase, anti-MDA5 and anti-PM/Scl. ILD is present in all subsets of IIM including juvenile myositis, but is more frequent in dermatomyositis and overlap myositis. IIM can also be associated with other presentations of respiratory involvement, namely pulmonary arterial hypertension, pleural disease, infections, drug-induced toxicity, malignancy and respiratory muscle weakness. Here, we critically review the current knowledge about adult and juvenile myositis-associated lung disease with a detailed description of therapeutics for chronic and rapidly progressive ILD. @ERSpublications Interstitial lung disease is a leading cause of morbidity in dermatomyositis/polymyositis

show abstract

“…The combination of pulse-dosed CYC and corticosteroids in 17 refractory patients resulted in significantly improved dyspnea, vital capacities, and CT findings. The results of the trial in question suggest that CYC (IV) can be more effective during the early stages of the disease (18). In addition, early initiation of immunosuppressive agents (within 1 month of steroid therapy) is one of the predictive factor for better prognosis for the patients with DM complicated pnemomediastinum (15).…”

Section: Discussionmentioning

confidence: 99%